Cargando…

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer

The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Memorial Slo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiao, Xi, Wei, Xin, Li, Shuang, Liu, Chang, Chen, Huan, Gong, Jifang, Li, Jian, Zhang, Xiaotian, Wang, Xicheng, Peng, Zhi, Qi, Changsong, Wang, Zhenghang, Wang, Yujiao, Wang, Yanni, Zhuo, Na, Zhang, Henghui, Lu, Zhihao, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096820/ https://www.ncbi.nlm.nih.gov/pubmed/33947957 http://dx.doi.org/10.1038/s41698-021-00172-5

Ejemplares similares

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
por: Wang, Yujiao, et al.
Publicado: (2022)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
por: Wang, Yanni, et al.
Publicado: (2022)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients
por: Wang, Yanni, et al.
Publicado: (2021)

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
por: Zhuo, Na, et al.
Publicado: (2022)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2021)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer
por: Lu, Zhihao, et al.
Publicado: (2019)

Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
por: Lu, Zhihao, et al.
Publicado: (2020)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis
por: Xu, Ting, et al.
Publicado: (2023)

Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study
por: Xie, Tong, et al.
Publicado: (2020)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial
por: Lu, Zhihao, et al.
Publicado: (2021)

Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer
por: Yao, Zhihao, et al.
Publicado: (2022)

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
por: Lu, Ming, et al.
Publicado: (2016)

Genetic differences between lung metastases and liver metastases from left-sided microsatellite stable colorectal cancer: next generation sequencing and clinical implications
por: Wang, Zhenghang, et al.
Publicado: (2021)

Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first‐line chemotherapy
por: Kou, Furong, et al.
Publicado: (2016)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
por: Xu, Yingying, et al.
Publicado: (2021)

Cuproptosis Depicts Immunophenotype and Predicts Immunotherapy Response in Lung Adenocarcinoma
por: Zhou, Wolong, et al.
Publicado: (2023)

Change of Body Weight and Macrophage Inhibitory Cytokine-1 during Chemotherapy in Advanced Gastric Cancer: What Is Their Clinical Significance?
por: Lu, Zhihao, et al.
Publicado: (2014)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

A Six-lncRNA Signature for Immunophenotype Prediction of Glioblastoma Multiforme
por: Gao, Ming, et al.
Publicado: (2021)

Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System
por: Ji, Zhi, et al.
Publicado: (2020)

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study
por: Li, Jie, et al.
Publicado: (2016)

Editorial: The role of immunophenotype in tumor immunotherapy response
por: Qin, Yujuan, et al.
Publicado: (2023)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features
por: Wang, Yakun, et al.
Publicado: (2019)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
por: Wang, Zhenghang, et al.
Publicado: (2020)

Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer
por: Wang, Jia‐Bin, et al.
Publicado: (2023)

The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study
por: Chen, Mifen, et al.
Publicado: (2022)

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study
por: Liu, Dan, et al.
Publicado: (2023)

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study
por: Zhang, Xiaodong, et al.
Publicado: (2019)

Immunophenotyping of pulmonary sarcomatoid carcinoma
por: Ma, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_erh37pj5f4d7gstsis8g7t7t64